Related Experiment Video
Updated: Jul 25, 2025
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
A high throughput antiviral screening platform for alphaviruses based on Semliki Forest virus expressing eGFP
Yu-Jia Shi1, Jia-Qi Li2, Hong-Qing Zhang2
1Hunan Normal University, School of Medicine, Changsha, 410081, China.
Abstract:
Alphaviruses, which contain a variety of mosquito-borne pathogens, are important pathogens of emerging/re-emerging infectious diseases and potential biological weapons. Currently, no specific antiviral drugs are available for the treatment of alphaviruses infection. For most highly pathogenic alphaviruses are classified as risk group-3 agents, the requirement of biosafety level 3 (BSL-3) facilities limits the live virus-based antiviral study. To facilitate the antiviral development of alphaviruses, we developed a high throughput screening (HTS) platform based on a recombinant Semliki Forest virus (SFV) which can be manipulated in BSL-2 laboratory. Using the reverse genetics approach, the recombinant SFV and SFV reporter virus expressing eGFP (SFV-eGFP) were successfully rescued. The SFV-eGFP reporter virus exhibited robust eGFP expression and remained relatively stable after four passages in BHK-21 cells. Using a broad-spectrum alphavirus inhibitor ribavirin, we demonstrated that the SFV-eGFP can be used as an effective tool for antiviral study. The SFV-eGFP reporter virus-based HTS assay in a 96-well format was then established and optimized with a robust Z' score. A section of reference compounds that inhibit highly pathogenic alphaviruses were used to validate that the SFV-eGFP reporter virus-based HTS assay enables rapid screening of potent broad-spectrum inhibitors of alphaviruses. This assay provides a safe and convenient platform for antiviral study of alphaviruses.
Insights
Researchers developed a safe and convenient high throughput screening (HTS) platform using a Semliki Forest virus (SFV) reporter virus. This platform facilitates the discovery of novel antiviral drugs for alphavirus infections in a BSL-2 laboratory setting.
Area of Science:
- Virology
- Infectious Diseases
- Drug Discovery
Background:
- Alphaviruses are significant emerging infectious disease agents and potential bioweapons.
- No specific antiviral drugs currently exist for alphavirus infections.
- High-security BSL-3 facilities limit research on dangerous alphaviruses.
Purpose of the Study:
- To develop a safe and accessible high throughput screening (HTS) platform for alphavirus antiviral drug discovery.
- To create a Semliki Forest virus (SFV) reporter system for use in BSL-2 laboratories.
Main Methods:
- Developed a recombinant SFV reporter virus (SFV-eGFP) using reverse genetics.
- Validated SFV-eGFP stability and expression in cell culture.
- Established and optimized an HTS assay using SFV-eGFP in a 96-well format.
- Validated the HTS assay with known alphavirus inhibitors.
Main Results:
- Successfully rescued and characterized a stable SFV-eGFP reporter virus.
- Demonstrated SFV-eGFP's utility as a tool for antiviral screening.
- Established a robust HTS assay with a high Z' score.
- Validated the platform's ability to screen for broad-spectrum alphavirus inhibitors.
Conclusions:
- The SFV-eGFP reporter virus provides a safe and convenient platform for alphavirus antiviral research.
- This HTS assay enables rapid screening of potential broad-spectrum alphavirus inhibitors.
- Facilitates the development of much-needed antiviral therapies for alphavirus infections.
